Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for January 2008
January 2, 2008
- PRWT Acquires Chemical Manufacturing Facility from Merck & Co., Inc.
- Biovail Announces Supply Agreement for Commercialization of Extended-Release Tramadol
- Use of Opioids to Treat Pain in Emergency Departments on the Rise, but Racial Differences in Opioid Use Still Exist
- IDM Pharma Announces Termination of Uvidem Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives
- Pfizer Inc Announces Completion of the Tender Offer Relating to Outstanding Shares of Coley Pharmaceutical Group, Inc.
- Beijing Med-Pharm Receives Business License for Alliance BMP Limited
- Covalence Ethical Ranking 2007
January 3, 2008
- Celgene/Pharmion Hart-Scott-Rodino (HSR) Thirty Day Waiting Period Expires
- Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia
- B-cell Chronic Lymphocytic Leukemia (B-CLL): Expanded Labeling for MabCampath in Europe
- Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals Against Rabies
- Phase Bioscience Announces New Collaboration with Centocor Research and Development
- Galapagos Enters Into Oncology Target Discovery Collaboration with Janssen Pharmaceutica
- Bruker AXS Announces Agreement to Acquire Elemental Analysis Company JUWE Laborgeraete GmbH
- Novacea Provides Corporate and Development Update
- Pfizer to Appeal Canadian Federal Court Ruling on Lipitor Patent; Court's Decision Will Have No Immediate Commercial Impact
- FDA Issues Communication Communication about an Ongoing Safety Review of ESAs
January 4, 2008
- 2007 - The Year in Drugs
- Illumina Announces Corporate Reorganization
- BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
- WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
- IMS Health Announces Restructuring Actions to Improve Operating Efficiencies, Address Client Priorities
- Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
January 7, 2008
- Magen BioSciences Licenses Dermatology Assets from Lilly
- Contract Research Organization Market - What Pharmaceutical and Biotechnology Companies Want
- Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate
- VaxGen Provides Update on Raven Transaction Progress
- Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
- Access Pharmaceuticals Closes Acquisition of Somanta Pharmaceuticals
- Encorium Group, Inc. Announces the Signing of a $2.0 Million Contract for Data Management Services for a Global Pharmaceutical Company
- ATMI Acquires LevTech
- Faust Pharmaceuticals Announces Research Agreement with Takeda
- Inclinix Secures $10 Million in Expansion Funding
- Omnicom's BBDO Invests in China's Shunya Communications Group
- NextGen Sciences Announces Commercial Alliance with Paragon Bioservices, Inc
- Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
- Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
- The GVK BIO Clinical Pharmacology Unit Granted Major Accreditations
- Synovate Healthcare Boosts Global Oncology Portfolio Through Acquisition of Oncology Inc.
- FDA MedWatch - Bisphosphonates- Possible Cause of Severe and Sometimes Incapacitating Bone, Joint, and/or Muscle Pain
- MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
- Cambrex Signs Agreement To Acquire ProSyntest AS
- Court of Appeals Upholds Verdicts in Favor of Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
January 8, 2008
- NicOx Signs Extension of Ophthalmology Agreement With Pfizer
- Cetero Research Adds DGD Research, Enhancing Their Therapeutic Capabilities and Expertise to Include Endocrinology and Metabolic Disorders
- Reckitt Benckiser Receives Hart-Scott-Rodino Antitrust Clearance for Acquisition of Adams Respiratory Therapeutics
- Cetero Research Adds DGD Research, Enhancing Their Therapeutic Capabilities and Expertise to Include Endocrinology and Metabolic Disorders
- Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases
- Boston Scientific Announces Court Decision
- Seattle Genetics Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin Lymphoma
- Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
- Introducing Latest Study on 'Optimizing Partnerships with Contract Organizations: Effective Management, Key Issues and the Development of Virtual Pharmacos'
- ViroPharma Provides Update on Vancocin
- Committee on Energy and Commerce Opens Investigation into Celebrity Drug Endorsements
- FDA Warnings Affected Prescriptions of Antidepressants to Youth
- Removing Thimerosal from Vaccines Did Not Reduce Autism Cases in California
- PII Acquires Pharmaterials Ltd
- Iris Pharma and Clirophtha Merger Creates Unique Ophthalmology CRO
- Iris Pharma and Clirophtha Merger Creates Unique Ophthalmology CRO
- Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech
- ResearchPoint Global Announces Addition of M2S to Network
- Acquisition of Lymphatix Brings VEGF Gene Rights and Technology to Catalyse Ark's Gene-Based Medicine Programmes
- Praxis' Patient Recruitment Campaign Saves 300 Days off Enrollment for Women's Health Study
- Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue
- Amgen Updates 2007 Adjusted EPS Guidance and Outlines 2008 Expense Outlook at the JP Morgan Healthcare Conference
- First Consulting Group Prevails at Court Hearing
January 9, 2008
- Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
- D.C. Council Passes Safe Rx Act
- Morphotek Announces Agreement for the Development of Antibodies to Treat Prostate Cancer
- Barr Confirms Patent Challenge of Eloxatin Injectable, 5mg/mL
- PPRS Renegotiation: Joint ABPI/DH Statement
- Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility
January 10, 2008
- Pfizer Wins Key New York State Court Ruling on Celebrex
- Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
- Invitrogen Announces Acquisition of CellzDirect
- Encorium Group, Inc. Announces Signing of $1.7 Million in Contracts with Leading International Biotechnology Company for Clinical Trials in Oncology and Rheumatology
- Jerini Announces Collaboration Agreement with Baxter to Develop Novel Peptide for Use in Therapeutic Protein Purification
- Noven Receives FDA Warning Letter Related to Mid-2007 Facility Inspection
January 11, 2008
- Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Lawsuits Against Several Companies for Patent Infringement
- RxElite Announces Acquisition of Assets of FineTech Laboratories
- CSS Informatics Signs Solutions Partner Agreement with Nimbus Partners
- Atlantis Holding Corp. Announces Merger With Medical Institutional Services, Inc.
January 14, 2008
- Compugen Announces GPCR Ligand Discovery and License Option Agreement With Merck
- Inspire Announces Its Termination of Bilastine Licensing Agreement
- Pfizer Receives Initial Communication from U.S. Patent and Trademark Office Regarding Lipitor Basic Patent
- Thimerosal-Autism Link Rejected by Maryland Court
- Galapagos Extends Drug Discovery Collaboration with Lilly in Nuclear Hormone Receptor Research
- Bridge Laboratories Receives $18 Million Financial Backing
- BLM, the Leading Independent Agency, to Combine with Arena Media Communications
- A.P. Pharma Announces Executive Officer Departure
- Supreme Court Declines to Consider Whether Those Near Death Have Right of Access to Experimental Drugs
January 15, 2008
- Genentech Announces Full Year and Fourth Quarter 2007 Results
- Forest Laboratories, Inc. Reports Q3'08 Diluted Earnings Per Share of $0.96. Raises FY2008 EPS Guidance Range to $3.35-$3.45 Excluding $0.15 per Share Licensing Charge
- Novo Nordisk Refocuses Its Activities Within Inhaled Insulin and Discontinues the Development of AERx
- Reps. Dingell, Stupak to Continue ENHANCE Trial Investigation
- First Head to Head Study Comparing Crestor and Lipitor Effects on the Treatment of Atherosclerosis
- Akrimax Pharmaceuticals Purchases Rouses Point Plant
January 16, 2008
- ACC Statement on Enhance Trial
- EU Antitrust: Commission Launches Sector Inquiry Into Pharmaceuticals with Unannounced Inspections
- NitroMed Reports on BiDil XR Progress Following FDA Meeting, Announces Restructuring and Suspension of BiDil Sales Force, and Retains Investment Bank to Advise on Strategic Options
- ImpactRx Broadens Innovative Research Capability Through Acquisition of Paragon Research and Consulting
- Sandoz Fully Cooperating with European Commission Investigation of the Pharmaceuticals Industry
- HIV/AIDS Update - Reyataz (atazanavir) Package Insert Revisions
- Canon Communications to Launch New Event for Drug and Medical Device Marketing
- FDA Issues a Public Health Advisory on Edetate Disodium (Marketed as Endrate and Generic Products)
January 17, 2008
- QLT Announces Visudyne Sales for Fourth Quarter and Fiscal Year 2007
- QLT Inc. Announces Initial Steps in Strategic Restructuring
- Ventana Responds to Extension of Roche's Unsolicited Tender Offer
- Novartis Achieves Record Results in 2007 Underscoring Benefits of Strategic Healthcare Portfolio
- Reps. Dingell, Stupak Raise Concerns, Questions on ENHANCE Trial
- AAJ Demands FDA Withdraw Rule Allowing Drug Companies to Claim Immunity for Failing to Warn Patients of Potential Drug Hazards
- FDA MedWatch - Edetate Disodium (marketed as Endrate and generic products) - Important Safety Considerations For Healthcare Professionals
- Eisai and MGI Pharma Announce Early Termination of HSR Waiting Period for Eisai's Acquisition of MGI Pharma
- Genedata Provides Expressionist Platform to Eisai Research Institute
- Malvern Instruments Acquires Viscotek Corporation
January 18, 2008
- Jan Marini Skin Research Suspends Sales of Popular Eyelash Products
- StemCells, Inc. Provides Batten's Clinical Trial Update
- Actavis Acquires Italian Manufacturing Site from Pfizer
- Roche Invests 430 Million Swiss Francs at Sites in Germany and Switzerland Centres for the Research, Development, Production and Filling of Innovative Biopharmaceuticals to be Expanded
- U.S. Appeals Court Upholds Finding that Abbott Infringed Innogenetics’ HCV Genotyping Patent, and Orders Abbott to Pay Innogenetics Monetary Damages and Sanctions
- Pfizer Statement on Chantix (varenicline) Labeling Update in the United States
- GTC Biotherapeutics Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
- Schering-Plough CEO to Buy $2 Million in Common Shares
- New Jersey Attorney General Announces Subpoena of Pharmaceutical Firm Over Marketing of Injectable Drug Enbrel
January 22, 2008
- CytRx Provides Update on Phase IIb Arimoclomol Clinical Trial for ALS
- Ortho Evra Prescribing Information Updated
- Roche to Acquire Ventana for $89.50 per share
- GSK Does Not Option XL784 for Further Development
- Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Teva's Launch of Generic Pantoprazole
- 19 Percent of Office-Based Physicians Refuse to See Pharmaceutical, Biotech and Medical Device Sales Reps
- Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
- Aureon Laboratories to Collaborate with Pfizer, Inc. to Establish Quantitative Biometrics for Assessing Therapeutic Response of Prostate Cancer Patients Treated with Hormone Therapy
- Teva to Acquire CoGenesys
- Elsevier Acquires Edra S.p.A
January 23, 2008
- Abbott Reports 16.1 Percent Sales Growth in Fourth Quarter
- Reps. Dingell, Stupak Continue Enhance Trial Inquiry
- Oversight and Government Reform Committee Chairman Waxman Requests FDA Provide Documents Regarding Drug Company Marketing Loophole
- Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKline's Rotarix
- Eisai Announces Satisfaction of Conditions to Tender Offer for MGI Pharma Shares
- Pfizer Reports Fourth-Quarter and Full-Year 2007 Results and 2008 Financial Guidance
- Bayer Establishes US Special Access Program for Leukine While Replacing Current Liquid Formulation
- Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
- U.S. Federal Trade Commission Clears Global Licensing and Development Agreement Between BioMS Medical and Lilly
- Direvo to Collaborate with Medimmune on Therapeutic Protease for the Treatment of CNS Diseases
- U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences' Claims
January 24, 2008
- Baxter Achieves Record Sales and Earnings for Full-Year 2007
- GlaxoSmithKline and TB Alliance Renew Tuberculosis Drug Discovery Program
- Stanford Study Finds Transplant Patient Thrives 2 Years After Stopping Immunosuppressive Drugs
January 25, 2008
- Amgen's Fourth Quarter 2007 Adjusted Earnings Per Share (EPS) Increased 11 Percent to $1.00; Full Year 2007 Adjusted EPS Increased 10 Percent to $4.29
- TransTech Pharma, Inc. Acquires Three Programs for the Treatment of Metabolic Disorders from Novo Nordisk
- Allergan, Inc. Comments on Botox (Botulinum Toxin Type A) Safety Profile
- ApoCell to Conduct Studies in Support of Novel Pfizer Cancer Drug Trial
- LabCorp Announces Definitive Agreement to Acquire Tandem Labs, Inc.
- EMEA Statement on the Safety of Gardasil
- Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
- EMEA Recommends New Warnings and Contraindications for Rosiglitazone
- Sen. Grassley Asks Questions About Controversy Over Delayed Release of Drug Study Involving Vytorin
- MicroIslet Announces Management Change and Receives Working Capital Loan
- FDA Issues Early Communication about an Ongoing Review of Vytorin
January 28, 2008
- Over-the-counter eardrops may cause hearing loss or damage
- Allergan, Inc. Responds to Public Citizen's Allegation Regarding a Fatality Following Botox Cosmetic Treatment
- Merck Receives Not Approvable Letter from FDA for OTC Mevacor (lovastatin) 20 mg
- German Federal Cartel Office Clears Celgene to Acquire Pharmion
- Abbott and Eisai Announce Changes in the Sales Scheme in Japan for Adalimumab, A Fully Human Monoclonal Anti-TNF- Antibody
- Gastrotech Signs Licensing Agreement with Eli Lilly Following Positive Clinical Data on Compound for Irritable Bowel Syndrome
- Canon Communications Announces Details of Drug Development Summit
- Bausch & Lomb and CrystalGenomics Announce R&D Collaboration
January 29, 2008
- Lilly Caps Successful Year with Strong Fourth-Quarter Results
- Eisai Completes Acquisition of MGI Pharma
- Theratechnologies Announces Review of Strategic Alternatives and Filing of Preliminary Base Shelf Prospectus for Up to $35 Million Equity Financing
- PAION Agreement with Lundbeck Comes Into Force, Securing Future Desmoteplase Development and EUR 8 Million Upfront-payment to PAION
- U.S. Pharmacopeia 8th Annual MEDMARX Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide
January 30, 2008
- FDA Sends Warning Letter to Novartis Vaccines and Diagnostics
- Teva Announces Wyeth Voids Standstill Agreement on Generic Protonix
- Merck Announces 2007 Financial Results Reflecting Revenue Growth from Key Products
- Wyeth Announces Launch of Own Generic Version of Protonix
- Neose Announces Discontinuation of NE-180 Program
- Kyowa Hakko Nine-month Operating Income up 20.6%; Raises Full-year Forecasts
- Record Operating Results for Roche Again in 2007
- Taisho Revises Earnings Forecasts for FY2007 Full Year
- Prasco to Distribute Wyeth's Own Generic Versions of Protonix Delayed-Release Tablets
- Allergan Reports Fourth Quarter Operating Results
- Common Drug-Releasing Coronary Stents Appear to Have Similar Clinical Outcomes
- Solvay Pharmaceuticals, Inc. Announces Retirement of CEO Laurence Downey and Appointment of Stephen Hill as New President and Chief Executive Officer
January 31, 2008
- Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
- P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company
- ImClone Systems Reports Fourth Quarter and Full Year 2007 Financial Results
- Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
- PsychoGenics Expands Drug Discovery Relationship with Eli Lilly and Company
- Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin Sales and Applications Seeking Two Product Approvals in 2009
- AstraZeneca PLC, Fourth Quarter and Full Year Results 2007
- Novo Nordisk: Financial statement for 2007
- Innate Pharma and Novo Nordisk A/S Partnership Refocused on the Inflammatory Field
- FDA MedWatch- Antiepileptic Drugs- FDA Analysis Showed Patients Receiving Antiepileptic Drugs Had Approximately Twice The Risk of Suicidal Behavior Or Ideation
